AI-Powered Medical Documentation Automation: Med Tech Incorp. Journey
From first customer on day 88 to a $17.9M exit after 1,298 days, Med Tech Incorp. grew an AI medical workflow tool despite 37% churn and early cash crunch.
- Idea: An Ai powered tool for medical practice to automate documentation, help with diagnostics und therapy, disease management, appointments. Runs local with strict data safety. Helps to reduce workload, treatment errors and optimizes therapy.
- Result: Sold for $17.9M on day 1298
- Peak MRR: $374.1k
- Final MRR: $367.3k · 2847 customers · team of 28
Early Cash Crunch and First Customer
The simulation began with a painful cash dip: on day 14 the company’s bank balance hit a low of $500. Survival instincts kicked in, and by day 88 the first medical practice signed on. That first contract proved the AI‑driven documentation tool could run locally with strict data safety, giving the founders a foothold and a modest cash infusion. The early scramble to stay afloat set the tone for a lean, cash‑conscious approach that would later pay off.
Revenue Milestones Amidst High Churn
Growth was measured in hard numbers. Med Tech Incorp. reached $1,000 MRR on day 125, $10,000 MRR on day 352, and $50,000 MRR on day 604. The peak came at day 1,279 with $374,100 MRR, settling at $367,263 MRR at exit. However, the churn rate hovered at a steep 37.4%, meaning a sizable slice of customers left each month. The company survived the churn by constantly adding new practices, but the metric highlighted a fragile retention engine that would later factor into the sale price.
Team Expansion and Cash Management
Hiring kept pace with revenue. The headcount grew to a maximum of 28 employees, all housed in a bigOffice setting. By the end of the 1,298‑day run the cash balance had risen to $479,415, a dramatic turnaround from the $500 trough. The larger team enabled more support for medical clients and helped ship the core AI features, but each new hire also added overhead. Balancing payroll against a high churn rate was a constant juggling act that the founders eventually resolved through the exit.
Exit and Valuation
After nearly three and a half years, the simulation concluded with a sale price of $17,852,480, matching the final valuation. The buyer paid for a product that could automate documentation, diagnostics, therapy planning, disease management, and appointments while keeping data on‑premise. The exit reflected both the impressive MRR and the lingering risk of churn, packaging the business as a high‑growth, high‑risk asset. The founders walked away with a tidy sum and a story that underscores the trade‑off between rapid scaling and customer retention.
Lessons
- Maintain a healthy cash runway early on; a $500 low point can jeopardize survival.
- Monitor churn closely—high growth can mask retention problems that affect valuation.
- Scale the team in line with sustainable revenue, not just headline MRR milestones.